Ballentine Partners LLC grew its position in Pfizer Inc. (NYSE:PFE – Get Rating) by 9.0% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 104,230 shares of the biopharmaceutical company’s stock after buying an additional 8,593 shares during the period. Ballentine Partners LLC’s holdings in Pfizer were worth $5,341,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of PFE. Front Street Capital Management Inc. increased its position in shares of Pfizer by 4.3% during the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock worth $268,000 after purchasing an additional 215 shares in the last quarter. Lindenwold Advisors increased its position in Pfizer by 1.0% during the 3rd quarter. Lindenwold Advisors now owns 21,151 shares of the biopharmaceutical company’s stock valued at $926,000 after buying an additional 216 shares in the last quarter. SRS Capital Advisors Inc. raised its stake in Pfizer by 1.6% in the second quarter. SRS Capital Advisors Inc. now owns 13,618 shares of the biopharmaceutical company’s stock valued at $714,000 after buying an additional 218 shares during the last quarter. Signet Financial Management LLC boosted its holdings in Pfizer by 0.6% in the third quarter. Signet Financial Management LLC now owns 34,338 shares of the biopharmaceutical company’s stock worth $1,503,000 after acquiring an additional 220 shares in the last quarter. Finally, Mitchell Mcleod Pugh & Williams Inc. increased its holdings in shares of Pfizer by 0.7% during the third quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 33,978 shares of the biopharmaceutical company’s stock valued at $1,487,000 after acquiring an additional 222 shares in the last quarter. Hedge funds and other institutional investors own 67.62% of the company’s stock.
Insider Activity
In other news, major shareholder Pfizer Inc acquired 1,811,594 shares of the business’s stock in a transaction that occurred on Friday, March 17th. The stock was purchased at an average cost of $2.76 per share, for a total transaction of $4,999,999.44. Following the completion of the transaction, the insider now owns 5,952,263 shares in the company, valued at $16,428,245.88. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.05% of the company’s stock.
Pfizer Stock Down 0.1 %
Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings data on Tuesday, January 31st. The biopharmaceutical company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.11. The firm had revenue of $24.30 billion for the quarter, compared to the consensus estimate of $24.40 billion. Pfizer had a return on equity of 42.03% and a net margin of 31.27%. The firm’s revenue was up 1.9% compared to the same quarter last year. During the same quarter last year, the business posted $1.08 earnings per share. Equities analysts forecast that Pfizer Inc. will post 3.3 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
A number of analysts recently commented on PFE shares. SVB Leerink lowered their target price on shares of Pfizer from $49.00 to $48.00 and set a “market perform” rating for the company in a research note on Wednesday, February 1st. UBS Group set a $45.00 price objective on shares of Pfizer in a report on Tuesday, March 14th. BMO Capital Markets reduced their target price on Pfizer from $55.00 to $53.00 and set an “outperform” rating for the company in a research note on Wednesday, February 1st. Atlantic Securities lowered their price target on Pfizer from $50.00 to $46.00 and set a “neutral” rating for the company in a research report on Wednesday, February 1st. Finally, Barclays cut their price objective on Pfizer from $49.00 to $44.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 1st. Eight analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $49.93.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
- First Republic Bank Is A Speculative Play, Here’s Why
- The WD-40 Company Bottoms With Reversal In Sight
- 3 Low-Cost Stock ETFs That Are Crushing It This Year
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
